Table 3.
Association of baseline atenolol with gout, HR (95% CI)
| Unadjusted | Age/sex/race Adjusted | |||||
|---|---|---|---|---|---|---|
| Without atenolol Events/Total | With atenolol Events/Total | HR (95% CI) | P | HR (95% CI) | P | |
| Chlorthalidone | 306/10563 | 12/437 | 1.01 (0.57–1.80) | 0.98 | 1.18 (0.66–2.11) | 0.58 |
| Amlodipine | 116/6293 | 4/229 | 1.03 (0.38–2.78) | 0.96 | 1.10 (0.41–3.00) | 0.85 |
| Lisinopril | 152/6028 | 7/262 | 1.12 (0.53–2.39) | 0.77 | 1.21 (0.56–2.59) | 0.63 |
| Overall | 574/23036 | 23/928 | 1.05 (0.69–1.60) | 0.80 | 1.18 (0.78–1.80) | 0.43 |
Abbreviations: HR, hazard ratio; CI, confidence interval
Note: These analyses are presented unadjusted and adjusted for age, sex, and race/ethnicity as atenolol was not a randomized medication.